Cover Image
市場調查報告書

免疫療法治療藥的全球市場:2016年∼2020年

Global Immunotherapy Drugs 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 355602
出版日期 內容資訊 英文 159 Pages
訂單完成後即時交付
價格
Back to Top
免疫療法治療藥的全球市場:2016年∼2020年 Global Immunotherapy Drugs 2016-2020
出版日期: 2016年03月29日 內容資訊: 英文 159 Pages
簡介

全球免疫療法治療藥市場預測在2016年∼2020年間將以年複合成長率 (CAGR) 11.52%的速度成長。

本報告提供全球免疫療法治療藥市場相關調查分析,提供您市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

  • 焦點

第2章 調查範圍

  • 市場概要
  • 主要供應商產品
  • 前提條件

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 主要市場焦點

第5章 概要:免疫療法

  • 免疫療法的種類
  • 主要的活動
  • 給付政策
  • 孤兒藥的指定與法規當局的認證

第6章 產品研發線

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 市場區隔:免疫療法類別

  • 單株抗體 (MAb)
  • 免疫查核點抑制劑
  • 疫苗
  • 非特異性免疫療法

第9章 市場區隔:各治療領域

第10章 地理區分

  • 各地理分類
  • 南北美洲
  • 歐洲·中東·非洲
  • 亞太地區

第11章 推動市場要素

第12章 推動因素的影響

第13章 市場課題

第14章 推動因素與課題的影響

第15章 市場趨勢

第16章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • F. Hoffmann-La Roche
  • AbbVie
  • Johnson & Johnson
  • Merck
  • Amgen
  • BMS
  • 其他卓越供應商

第17章 附錄

第18章 關於Technavio

圖表

目錄
Product Code: IRTNTR8772

About Immunotherapy Drugs

Immunotherapy enhances the innate powers of the immune system. The properties of the immune system to fight abnormal cells give immunotherapy drugs the chance of successfully fighting diseases such as cancer, respiratory, infectious, and autoimmune disorders.

Technavio's analysts forecast the global immunotherapy drugs market to grow at a CAGR of 11.52% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global immunotherapy drugs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of immunotherapy drugs used to treat cancer, respiratory, infectious, autoimmune, and inflammatory diseases. It also considers the revenues to be generated from the sales of drugs, which are expected to be launched into the market, along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Immunotherapy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company (BMS)
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson Private Ltd.
  • Merck & Co. Inc.

Other Prominent Vendors

  • AB Science
  • Ablynx
  • Acorda Therapeutics
  • ADC Therapeutics
  • Aduro Biotech
  • Advantagene
  • Advaxis
  • Agensys Inc.
  • Agenus Inc.
  • Alder Biopharmaceuticals
  • AlphaVax
  • Altor BioScience
  • Antares Pharma
  • Antigen Express
  • Argos Therapeutics Inc.
  • Astellas Pharma
  • AstraZeneca
  • AVAX Technologies
  • Bavarian Nordic
  • Baxter
  • Bayer
  • Biogen
  • Biotech Pharmaceutical
  • Biothera
  • Boehringer Ingelheim
  • Can-Fite BioPharma
  • Celgene
  • Celldex Therapeutics
  • Celltrion
  • Cel-Sci
  • ChemoCentryx
  • Chugai Pharmaceutical
  • Coherus BioSciences
  • CTI BioPharma
  • CureVac
  • Cytos Biotachnology
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • Fortress Biotech
  • Galena Biopharma
  • Genexine
  • Genmab
  • Gilead Sciences
  • GSK
  • GlobeImmune
  • Gradalis
  • Heat Biologics
  • Hospira
  • Idera
  • Immatics
  • ImmunoCellular Therapeutics
  • Immunomedics
  • ImmuPharma
  • Immutep
  • Incyte
  • Inovio Pharmaceuticals
  • Intas Pharmaceuticals
  • Invion
  • ISA Pharmaceuticals
  • Janssen Biotech
  • Juvaris Biotherapeutics
  • KaloBios Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lexicon Pharmaceuticals
  • MedImmune
  • Morphotek
  • Neovii Biotech
  • Northwest Biotherapeutics
  • Novartis
  • NovaRx
  • Novo Nordisk
  • OncoMed Pharmaceuticals
  • Oncothyreon
  • Oncovir Inc.
  • Opexa Therapeutics Inc.
  • Oxford BioMedica
  • Pfizer
  • Prima BioMed
  • Principia
  • Progenics
  • Provectus Biopharmaceuticals
  • Regeneron
  • Sandoz
  • Sanofi
  • Santarus
  • Seattle Genetics
  • Sotio
  • Spectrum Pharmaceuticals
  • Takeda
  • TG Therapeutics
  • Transgene
  • UbiVac
  • UCB
  • Vaccinex
  • Vaccinogen
  • Vaxon Biotech
  • Vertex Pharmaceuticals
  • Vical
  • Vitae Pharmaceuticals
  • XBiotech

Market driver

  • Growing prevalence of cancer and autoimmune diseases
  • For a full, detailed list, view our report

Market challenge

  • Patent expiries of top-selling drugs
  • For a full, detailed list, view our report

Market trend

  • Increase in awareness programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Assumptions

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview: Immunotherapy

  • Types of immunotherapy
  • Key events
  • Reimbursement policies
  • Orphan drug designation and regulatory approvals

PART 06: Pipeline portfolio

  • Anticipated number of immuno-oncology pipeline assets with single and multiple indications by 2020

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by type of immunotherapy

  • mAbs
  • Immune checkpoint inhibitors
  • Vaccines
  • Non-specific immunotherapies

PART 09: Market segmentation by therapy area

PART 10: Geographical segmentation

  • Global immunotherapy drugs market by geographical segmentation 2015-2020
  • Immunotherapy drugs market in Americas
  • Immunotherapy drugs market in EMEA
  • Immunotherapy drugs market in APAC

PART 11: Market drivers

  • Growing prevalence of cancer and autoimmune diseases
  • Rise in older population
  • Increase in demand for mAbs
  • Patient assistance programs
  • Promising pipeline

PART 12: Impact of drivers

PART 13: Market challenges

  • Patent expiries of top-selling drugs
  • High costs of biologicals
  • Poor diagnosis and screening
  • Adverse effects
  • Stringent regulations

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Increase in awareness programs
  • Emergence of targeted and combination therapies
  • Emergence of biosimilars
  • Strategic alliances
  • Expected entry of novel vaccines

PART 16: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • F. Hoffmann-La Roche
  • AbbVie
  • Johnson & Johnson
  • Merck
  • Amgen
  • BMS
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Types of immunotherapy
  • Exhibit 03: Key events in discovery and approvals of immunotherapy drugs
  • Exhibit 04: Immunotherapy drugs approved by US FDA in 2015
  • Exhibit 05: US FDA orphan drug designations and approvals list for immunotherapy drugs
  • Exhibit 06: EU orphan drug designations and approvals list for immunotherapy drugs
  • Exhibit 07: Phase III pipeline molecules for mAbs
  • Exhibit 08: Phase II pipeline molecules for mAbs
  • Exhibit 09: Phase I pipeline molecules for mAbs
  • Exhibit 10: Pipeline molecules for immune checkpoint inhibitors
  • Exhibit 11: Phase III pipeline molecules for vaccines
  • Exhibit 12: Phase II pipeline molecules for vaccines
  • Exhibit 13: Phase I pipeline molecules for vaccines
  • Exhibit 14: Near-launch immuno-oncology pipeline assets
  • Exhibit 15: Global immunotherapy drugs market 2015-2020 ($ billions)
  • Exhibit 16: Factors influencing global immunotherapy drugs market
  • Exhibit 17: Challenges faced by US immunologists while prescribing immunotherapy drugs 2015
  • Exhibit 18: SWOT analysis of global immunotherapy drugs market
  • Exhibit 19: Five forces analysis
  • Exhibit 20: Market segmentation by type of immunotherapy drug
  • Exhibit 21: Timeline of mAbs approval for cancer by US FDA
  • Exhibit 22: Timeline of mAbs approval for autoimmune, respiratory, and ophthalmic diseases by US FDA
  • Exhibit 23: Global mAbs market 2015-2020 ($ billions)
  • Exhibit 24: Key drivers and challenges of global monoclonal antibodies drugs market
  • Exhibit 25: Top vendor offerings in global mAbs market
  • Exhibit 26: Global immune checkpoint inhibitors market 2015-2020 ($ billions)
  • Exhibit 27: Key driver and challenge for global immune checkpoint inhibitors market
  • Exhibit 28: Top vendor offerings in global immune checkpoint inhibitors market
  • Exhibit 29: Global vaccines market 2015-2020 ($ billions)
  • Exhibit 30: Segmentation of global vaccines market by application 2015
  • Exhibit 31: Key drivers and challenges of global vaccines market
  • Exhibit 32: Top vendor offerings in global vaccines market
  • Exhibit 33: Global non-specific immunotherapies market 2015-2020 ($ billions)
  • Exhibit 34: Key drivers and challenges of global non-specific immunotherapies market
  • Exhibit 35: Top vendor offerings in global non-specific immunotherapies market
  • Exhibit 36: Segmentation of global immunotherapy drugs market by type of immunotherapy 2015
  • Exhibit 37: Global immunotherapy drugs market; YoY revenue and growth rate based on type of immunotherapy 2015-2020 ($ billions)
  • Exhibit 38: Global immunotherapy drugs market segmentation by therapy area
  • Exhibit 39: Segmentation of global immunotherapy drugs market by therapy area 2015
  • Exhibit 40: Segmentation of global immunotherapy drugs market by geography 2015
  • Exhibit 41: Global immunotherapy drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 42: Immunotherapy drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 43: Market share in the Americas by type of immunotherapy 2015
  • Exhibit 44: Immunotherapy drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 45: Market share in Europe by type of immunotherapy 2015
  • Exhibit 46: Immunotherapy drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 47: Market share in APAC by type of immunotherapy 2015
  • Exhibit 48: Global immunotherapy drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
  • Exhibit 49: Global incidence of cancers 2015 and 2020
  • Exhibit 50: Population aged 60 years and over: World, developed, and developing regions (millions)
  • Exhibit 51: Patient assistance programs for immunotherapy drugs
  • Exhibit 52: Some pipeline molecules for immunotherapy drugs
  • Exhibit 53: Impact of drivers
  • Exhibit 54: Approvals and patent expiries of top-selling immunotherapy drugs
  • Exhibit 55: Average annual treatment cost per patient for some immunotherapy drugs 2014 ($ millions)
  • Exhibit 56: Impact of drivers and challenges
  • Exhibit 57: Expected combination regimen launches in immune-oncology 2015-2020
  • Exhibit 58: Market share analysis of top vendors0
  • Exhibit 59: Competitive assessment of top 10 immunotherapy drugs 2015 ($ billions)1
  • Exhibit 60: YoY sales comparison of top five immunotherapy drugs 2013-2015 ($ billions)1
  • Exhibit 61: F. Hoffmann-La Roche: Immunotherapy drugs segmentation by revenue 20152
  • Exhibit 62: F. Hoffmann-La Roche: Top-selling immunotherapy drugs 20152
  • Exhibit 63: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
  • Exhibit 64: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)4
  • Exhibit 65: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)5
  • Exhibit 66: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
  • Exhibit 67: F. Hoffmann-La Roche: MabThera/Rituxan geographic segmentation by revenue 20156
  • Exhibit 68: F. Hoffmann-La Roche: YoY revenue and growth rate of Avastin 2012-2015 ($ billions)7
  • Exhibit 69: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin 2012-2015 ($ billions)8
  • Exhibit 70: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in US 2013-2015 ($ billions)8
  • Exhibit 71: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in EU 2013-2015 ($ billions)8
  • Exhibit 72: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in Japan 2013-2015 ($ millions)9
  • Exhibit 73: F. Hoffmann-La Roche: YoY revenue and growth rate of Perjeta 2012-2015 ($ billions)0
  • Exhibit 74: F. Hoffmann-La Roche: YOY revenue and growth rate of Kadcyla 2013-2015 ($ billions)1
  • Exhibit 75: F. Hoffmann-La Roche: Key takeaways3
  • Exhibit 76: AbbVie: Immunotherapy drugs segmentation by revenue 20154
  • Exhibit 77: AbbVie: YoY revenue and growth rate of HUMIRA 2013-2015 ($ billions)5
  • Exhibit 78: AbbVie: YoY revenue and growth rate of HUMIRA in US 2013-2015 ($ billions)5
  • Exhibit 79: AbbVie: YoY revenue and growth rate of HUMIRA in ROW 2013-2015 ($ billions)5
  • Exhibit 80: AbbVie: Sales of HUMIRA in major markets 20156
  • Exhibit 81: AbbVie: Key takeaways7
  • Exhibit 82: Johnson & Johnson: Key immunotherapy drugs segmentation by revenue 20158
  • Exhibit 83: Johnson & Johnson: Top-selling immunotherapy drugs 20158
  • Exhibit 84: Johnson & Johnson: YoY revenue and growth rate of Remicade 2012-2015 ($ billions)9
  • Exhibit 85: Johnson & Johnson: YoY revenue and growth rate of Stelara 2012-2015 ($ billions)0
  • Exhibit 86: Johnson & Johnson: YoY revenue and growth rate of Stelara in US 2012-2015 ($ billions)0
  • Exhibit 87: Johnson & Johnson: YoY revenue and growth rate of Stelara in ROW 2012-2015 ($ millions)0
  • Exhibit 88: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2012-2015 ($ billions)1
  • Exhibit 89: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in the US 2012-2015 ($ billions)1
  • Exhibit 90: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in ROW 2012-2015 ($ billions)2
  • Exhibit 91: Johnson & Johnson: Key takeaways3
  • Exhibit 92: Merck: Business segmentation by revenue 20154
  • Exhibit 93: Merck: Immunotherapy drugs segmentation by revenue 20155
  • Exhibit 94: Merck: Top-selling immunotherapy drugs 20156
  • Exhibit 95: Merck: YoY revenue and growth rate of Gardasil/Gardasil9 2012-2015 ($ billions)7
  • Exhibit 96: Merck: YoY revenue and growth rate of ProQuad/M-M-R II/Varivax 2012-2015 ($ billions)8
  • Exhibit 97: Merck: YoY revenue and growth rate of Zostavax 2012-2015 ($ millions)8
  • Exhibit 98: Merck: YoY revenue and growth rate of Pneumovax 23 2012-2015 ($ millions)9
  • Exhibit 99: Merck: YoY revenue and growth rate of RotaTeq 2012-2015 ($ millions)9
  • Exhibit 100: Merck: Key takeaways2
  • Exhibit 101: Amgen: Top-selling immunotherapy drugs 20153
  • Exhibit 102: Amgen: YoY revenue and growth rate of Enbrel in US and Canada 2012-2015 ($ billions)4
  • Exhibit 103: Amgen: YoY revenue and growth rate of Enbrel in US 2012-2015 ($ billions)4
  • Exhibit 104: Amgen: YoY revenue and growth rate of Enbrel in Canada 2012-2015 ($ millions)4
  • Exhibit 105: Amgen: YoY revenue and growth rate generated from net product sales of Xgeva 2012-2015 ($ billions)5
  • Exhibit 106: Amgen: YoY revenue and growth rate generated from net product sales of Prolia 2012-2015 ($ billions)5
  • Exhibit 107: Amgen: YoY revenue and growth rate of Vectibix in US 2012-2015 ($ millions)6
  • Exhibit 108: Amgen: YoY revenue and growth rate of Vectibix in ROW 2012-2015 ($ millions)6
  • Exhibit 109: Amgen: Key takeaways9
  • Exhibit 110: BMS: Business segmentation by revenue 20150
  • Exhibit 111: BMS: Immunotherapy drugs segmentation by revenue 20150
  • Exhibit 112: BMS: Top-selling immunotherapy drugs 20151
  • Exhibit 113: BMS: YoY revenue and growth rate of Orencia 2012-2015 ($ billions)2
  • Exhibit 114: BMS: YoY revenue and growth rate generated from net product sales of Yervoy 2012-2015 ($ billions)2
  • Exhibit 115: BMS: YoY revenue and growth rate of Erbitux in US, Canada, and Japan 2012-2015 ($ millions)3
  • Exhibit 116: BMS: Key takeaways
Back to Top